Last updated: March 13, 2026
What is NDC 23155-0785?
NDC 23155-0785 is a drug identified in the National Drug Code directory, typically representing a specific formulation and package size. Based on available data, this NDC corresponds to Adalimumab (Humira), a biologic used primarily for autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and psoriasis.
Market Overview
Market Size
The global biologics market was valued at approximately $385 billion in 2022, with monoclonal antibodies (mAbs) like adalimumab representing a significant segment. The U.S. dominates the market, accounting for over 45% of global sales. The biologic segment is growing at a compound annual growth rate (CAGR) of around 8–10%.
Key Competitors
- Humira (AbbVie): The brand leader, with global sales exceeding $20 billion annually prior to patent expiration.
- Amjevita (Amgen/AbbVie): Biosimilar launched in 2016, capturing market share.
- Cyltezo (Boehringer Ingelheim): Another biosimilar approved in 2017.
- Zirabev (Celltrion): Biosimilar gaining traction.
Patent and Biologics Market Trends
- Patent expiry of Humira in multiple markets, including Europe (2023) and the U.S. (2023–2024), opens markets for biosimilars.
- Biosimilar penetration in the U.S. reached approximately 55% of Humira’s market share by 2022.
- Patent challenges and legal disputes persist, impacting pricing and supply.
Regulatory Environment
- Biosimilar approvals by FDA in recent years have increased, with the agency easing pathways for biosimilar market entry.
- Pathways include 351(k) application process, which requires demonstration of biosimilarity to the reference product.
Price Projections
Historical Pricing Data
- Humira (brand): List price in the U.S. was about $6,000 per month in 2021.
- Biosimilars: Typically priced 15–30% below the brand. Amjevita listed at ~$4,000 per month in 2022.
- Average wholesale price (AWP) for adalimumab biosimilars: ranged from $3,800 to $4,200.
Future Pricing Trends
- Post-patent expiration, biosimilar prices are projected to decline further, reaching 50–60% of the original brand price within 2–3 years.
- Market competition and increased biosimilar adoption might reduce prices to around $2,000–$2,500 per month per dose in the U.S. over the next 3–5 years.
- Price erosion could be influenced by policy changes, such as penalties for brand-name drug monopolies or incentives for biosimilar use.
Factors Influencing Price Movements
- Patent litigation outcomes
- Manufacturer scale and biosimilar production capacity
- Payer formulary policies
- Patient access programs and discounts
Price Projection Summary Table
| Year |
Estimated Biosimilar Price (USD/month) |
Approximate % of Humira (Brand) Price |
| 2023 |
$3,600 – $4,200 |
60–70% |
| 2024 |
$2,800 – $3,500 |
45–58% |
| 2025 |
$2,000 – $2,800 |
33–47% |
Revenue Forecasts
- Assuming unit sales volumes increase due to biosimilar adoption, global sales for adalimumab could decline by 30–50% over 5 years.
- The U.S. market could see a 20–35% reduction in revenues for Humira as biosimilar uptake accelerates.
- Biosimilar sales are projected to add approximately $4–6 billion annually in the U.S., driven by generic competition.
Key Risks and Drivers
- Regulatory delays or new legal challenges affecting biosimilar approval and market entry.
- Changes in healthcare policies favoring biosimilars.
- Physician and patient acceptance rates.
- Price reductions driven by increased competition.
Conclusions
The market for NDC 23155-0785 (Adalimumab) is transitioning from high-priced brand dominance to biosimilar-driven competition. Pricing is expected to decline substantially over the next few years, with potential price points in the $2,000–$2,500 range per month in the U.S., driven by increased biosimilar adoption and competition.
Key Takeaways
- The patent expiration of Humira is opening the U.S. market to multiple biosimilars.
- Biosimilar prices will decrease approximately 50–60% within 3 years of market entry.
- Total market revenue for adalimumab products is expected to decline over the next five years due to biosimilar penetration.
- Pricing strategies, regulatory approvals, and healthcare policy will heavily influence future prices.
- Market growth for biosimilars will likely offset lower prices with increased volume.
FAQs
Q1: What led to the decline in Humira’s price?
Patent expirations and biosimilar entries reduce the dominant drug's pricing power.
Q2: How do biosimilars compare in terms of effectiveness?
Biosimilars are required to demonstrate biosimilarity in efficacy, safety, and quality, making them comparable to the reference product.
Q3: When will biosimilar prices stabilize?
Prices are expected to stabilize 2–3 years after market entry, at approximately 50% or less of the original brand price.
Q4: What is the impact of biosimilar adoption on pharmaceutical revenues?
Revenues decline for the original brand but increase overall market volume and biosimilar revenues.
Q5: How might policy changes influence future prices?
Policy incentives for biosimilar use or penalties for brand-name drug monopolies can further accelerate price reductions.
References
- IQVIA. (2022). Biologics and biosimilars market report.
- FDA. (2022). Guidance for industry: Biosimilar product development.
- EvaluatePharma. (2022). World Preview 2022: Outlook to 2027.
- IMS Health. (2022). The evolving biosimilars landscape.
- U.S. Patent and Trademark Office. (2023). Patent expiration data for biologics.
